Superiority of Stent-Grafts for In-Stent Restenosis in the Superficial Femoral Artery
Authors:
- 1 February 2015
- journal article
- research article
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 22 (1) , 1-10
Abstract
Purpose: To evaluate the short- and midterm outcomes of the Viabahn endoprosthesis with Propaten Bioactive Surface vs. standard balloon angioplasty for treatment of in-stent restenosis in the superficial femoral artery. Methods: Between June 2010 and February 2012, 83 patients with superficial femoral artery in-stent and Rutherford category 2 to 5 ischemia were enrolled at 7 sites participating in this prospective randomized controlled study (RELINE; ClinicalTrials.gov; identifier NCT01108861). The patients were randomized to treatment with either the heparin-bonded Viabahn endoprosthesis (n=39: 29 men; mean age 67.7±9.8 years) or a standard angioplasty balloon (n=44: 32 men; mean age 69.0±9.7 years). The primary effectiveness outcome was primary patency at 12 months, defined as no restenosis/occlusion within the target lesion based on duplex ultrasound and no target lesion revascularization. The primary safety endpoint was the incidence of serious device-related adverse events within 30 days of the procedure. Results: All patients randomized to receive dilation or the Viabahn stent-graft were treated according to their assignment. The technical success was 100% for the Viabahn group and 81.8% for the angioplasty group (p=0.002) owing to 9 patients requiring a bailout procedure after unsuccessful angioplasty. The 12-month primary patency rates were 74.8% for the Viabahn group and 28.0% for the angioplasty group (p<0.001). Excluding the 9 angioplasty patients who received bailout stenting, the primary patency for optimal balloon angioplasty was 37.0% (p<0.001). Three patients experienced device-related adverse events within 30 days: occlusion of the target lesion (Viabahn group), peripheral embolization (angioplasty group), and reocclusion of the target lesion (angioplasty group). Conclusion: In this study, the treatment of femoropopliteal in-stent restenosis with a Viabahn endoprosthesis showed significantly better results than treatment with a standard balloon at 1 year.Keywords
This publication has 22 references indexed in Scilit:
- Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal LesionsJACC, 2013
- Viabahn for femoropopliteal in-stent restenosisAnnals of Saudi Medicine, 2012
- Effective Treatment of Femoropopliteal In-Stent Restenosis With Stent GraftsJournal of Vascular Surgery, 2011
- Nitinol Stent Implantation Versus Balloon Angioplasty for Lesions in the Superficial Femoral Artery and Proximal Popliteal ArteryCirculation: Cardiovascular Interventions, 2010
- Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesionsCatheterization and Cardiovascular Interventions, 2009
- Nitinol Stent Implantation Versus Percutaneous Transluminal Angioplasty in Superficial Femoral Artery Lesions up to 10 cm in LengthCirculation, 2007
- Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)Journal of Vascular Surgery, 2007
- Determinants of the Severity of Functional Tricuspid RegurgitationThe American Journal of Cardiology, 2006
- Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral ArteryNew England Journal of Medicine, 2006
- Trends, complications, and mortality in peripheral vascular surgeryJournal of Vascular Surgery, 2006